Faron Pharmaceuticals Oy.
81 announcements.
81 announcements.
| Time | Date | Ticker | Company | Announcement |
|---|---|---|---|---|
| 12:05 | 03-03-2025 | FARN | Faron Pharmaceuticals Oy | FDA Grants Orphan Drug Designation |
| 12:00 | 28-02-2025 | FARN | Faron Pharmaceuticals Oy | Notice of Annual General Meeting |
| 07:30 | 27-02-2025 | FARN | Faron Pharmaceuticals Oy | Positive EMA Opinion on Orphan Drug Designation |
| 07:15 | 27-02-2025 | FARN | Faron Pharmaceuticals Oy | Annual Report 2024 published |
| 07:00 | 27-02-2025 | FARN | Faron Pharmaceuticals Oy | Financial Statement 1 January to 31 December 2024 |
| 10:00 | 19-02-2025 | FARN | Faron Pharmaceuticals Oy | Notice of Financial Statement and Annual Report |
| 12:00 | 14-02-2025 | FARN | Faron Pharmaceuticals Oy | Holding(s) in Company |
| 07:30 | 11-02-2025 | FARN | Faron Pharmaceuticals Oy | Change of Broker |
| 15:00 | 06-02-2025 | FARN | Faron Pharmaceuticals Oy | Holding(s) in Company |
| 07:00 | 06-02-2025 | FARN | Faron Pharmaceuticals Oy | Results of Oversubscribed Placing |
| 16:30 | 05-02-2025 | FARN | Faron Pharmaceuticals Oy | Proposed Issue and Placing |
| 07:00 | 31-01-2025 | FARN | Faron Pharmaceuticals Oy | Final Patient Identified for BEXMAB Phase II Study |
| 07:00 | 13-12-2024 | FARN | Faron Pharmaceuticals Oy | Faron’s Financial Calendar for 2025 |
| 07:00 | 27-11-2024 | FARN | Faron Pharmaceuticals Oy | Positive Phase 2 Interim Results from BEXMAB Trial |
| 07:00 | 05-11-2024 | FARN | Faron Pharmaceuticals Oy | Shareholders’ Nomination Board |
| 07:00 | 22-10-2024 | FARN | Faron Pharmaceuticals Oy | Faron’s Capital Markets Day 2024 |
| 07:00 | 30-08-2024 | FARN | Faron Pharmaceuticals Oy | Grant of options |
| 07:00 | 27-08-2024 | FARN | Faron Pharmaceuticals Oy | Faron 2024 Half-Year Financial Results |
| 07:00 | 27-08-2024 | FARN | Faron Pharmaceuticals Oy | FDA Grants Fast Track Designation for Bexmarilimab |
| 07:00 | 20-08-2024 | FARN | Faron Pharmaceuticals Oy | Notice of Half-Year Financial Results |
| 07:00 | 08-08-2024 | FARN | Faron Pharmaceuticals Oy | Appointment of Chief Financial Officer |
| 10:00 | 07-08-2024 | FARN | Faron Pharmaceuticals Oy | Grant of options |
| 08:30 | 06-08-2024 | FARN | Faron Pharmaceuticals Oy | Faron Appoints Dr. Petri Bono as new CMO |
| 07:00 | 11-07-2024 | FARN | Faron Pharmaceuticals Oy | Faron Announces Positive FDA Feedback |
| 14:00 | 25-06-2024 | FARN | Faron Pharmaceuticals Oy | Update on settlement |
| 10:30 | 25-06-2024 | FARN | Faron Pharmaceuticals Oy | Holding(s) in Company - Replacement |
| 12:45 | 24-06-2024 | FARN | Faron Pharmaceuticals Oy | Holding(s) in Company |
| 12:45 | 24-06-2024 | FARN | Faron Pharmaceuticals Oy | Holding(s) in Company |
| 12:45 | 24-06-2024 | FARN | Faron Pharmaceuticals Oy | Holding(s) in Company |
| 12:45 | 24-06-2024 | FARN | Faron Pharmaceuticals Oy | Holding(s) in Company |
| 13:00 | 20-06-2024 | FARN | Faron Pharmaceuticals Oy | New shares registered with Finnish Trade Register |
| 07:00 | 20-06-2024 | FARN | Faron Pharmaceuticals Oy | Fully subscribed EUR 30.7 million share offering |
| 08:00 | 05-06-2024 | FARN | Faron Pharmaceuticals Oy | Proposed REX Retail Offer |
| 07:00 | 04-06-2024 | FARN | Faron Pharmaceuticals Oy | Faron commences a share offering |
| 16:00 | 17-05-2024 | FARN | Faron Pharmaceuticals Oy | Issuance of warrants |
| 07:00 | 13-05-2024 | FARN | Faron Pharmaceuticals Oy | Replacement – Board Change |
| 14:00 | 30-04-2024 | FARN | Faron Pharmaceuticals Oy | Update on financial status |
| 13:00 | 30-04-2024 | FARN | Faron Pharmaceuticals Oy | Board Change |
| 07:00 | 08-04-2024 | FARN | Faron Pharmaceuticals Oy | Appointment of Chief Executive Officer |
| 07:10 | 08-04-2024 | FARN | Faron Pharmaceuticals Oy | Approval of Warrant Terms and Conditions |
| 07:05 | 08-04-2024 | FARN | Faron Pharmaceuticals Oy | Decisions of the Board of Directors |
| 12:00 | 05-04-2024 | FARN | Faron Pharmaceuticals Oy | Results of the Annual General Meeting |
| 07:00 | 04-04-2024 | FARN | Faron Pharmaceuticals Oy | Announcement of Placing |
| 07:00 | 28-03-2024 | FARN | Faron Pharmaceuticals Oy | Issue of Warrants to IPF Funding Update |
| 10:00 | 26-03-2024 | FARN | Faron Pharmaceuticals Oy | Faron´s Annual Report 2023 |
| 07:00 | 18-03-2024 | FARN | Faron Pharmaceuticals Oy | Additional Positive Data from Phase 1 of BEXMAB |
| 14:00 | 13-03-2024 | FARN | Faron Pharmaceuticals Oy | Notice of Annual General Meeting 2024 |
| 07:00 | 13-03-2024 | FARN | Faron Pharmaceuticals Oy | Financial Statement January 1 to December 31 2023 |
| 07:00 | 04-03-2024 | FARN | Faron Pharmaceuticals Oy | Binding commitments for convertible loans |
| 16:00 | 28-02-2024 | FARN | Faron Pharmaceuticals Oy | Replacement - Update to 2024 Financial Calendar |
| 14:00 | 21-02-2024 | FARN | Faron Pharmaceuticals Oy | Continued Negotiations Regarding Events of Default |
| 10:30 | 19-02-2024 | FARN | Faron Pharmaceuticals Oy | Events of Default |
| 07:00 | 31-01-2024 | FARN | Faron Pharmaceuticals Oy | Further re: Exercise of options |
| 07:00 | 25-01-2024 | FARN | Faron Pharmaceuticals Oy | BEXMAB Insights into Patient Profiles |
| 13:00 | 19-01-2024 | FARN | Faron Pharmaceuticals Oy | Exercise of options - Issue of equity |
| 07:00 | 09-01-2024 | FARN | Faron Pharmaceuticals Oy | First Patient Dosed in Ph 2 of the BEXMAB Trial |
| 07:00 | 22-12-2023 | FARN | Faron Pharmaceuticals Oy | Faron’s Financial Calendar for 2024 |
| 07:00 | 11-12-2023 | FARN | Faron Pharmaceuticals Oy | Phase 1 BEXMAB data presented at ASH |
| 07:00 | 04-12-2023 | FARN | Faron Pharmaceuticals Oy | Grant of options |
| 08:13 | 06-11-2023 | FARN | Faron Pharmaceuticals Oy | Faron Initiates Phase 2 Part of BEXMAB Study |
| 07:00 | 06-11-2023 | FARN | Faron Pharmaceuticals Oy | Faron Initiates Phase 2 Part of BEXMAB Study |
| 13:00 | 27-10-2023 | FARN | Faron Pharmaceuticals Oy | Manager's transactions |
| 07:15 | 27-10-2023 | FARN | Faron Pharmaceuticals Oy | Exercise of options |
| 07:00 | 27-10-2023 | FARN | Faron Pharmaceuticals Oy | Results of Placing |
| 16:30 | 26-10-2023 | FARN | Faron Pharmaceuticals Oy | Proposed Issue and Placing |
| 07:00 | 11-10-2023 | FARN | Faron Pharmaceuticals Oy | Faron Announces Positive BEXMAB Study Update |
| 16:00 | 22-09-2023 | FARN | Faron Pharmaceuticals Oy | Board Changes |
| 11:00 | 22-09-2023 | FARN | Faron Pharmaceuticals Oy | Results of EGM |
| 07:00 | 21-09-2023 | FARN | Faron Pharmaceuticals Oy | Faron Appoints Interim Chief Medical Officer |
| 07:00 | 08-09-2023 | FARN | Faron Pharmaceuticals Oy | Change in the Board of Directors |
| 10:00 | 01-09-2023 | FARN | Faron Pharmaceuticals Oy | Notice of EGM |
| 14:00 | 31-08-2023 | FARN | Faron Pharmaceuticals Oy | Exercise of options |
| 07:00 | 29-08-2023 | FARN | Faron Pharmaceuticals Oy | FDA Orphan Drug Designation for Bexmarilimab |
| 07:01 | 29-08-2023 | FARN | Faron Pharmaceuticals Oy | Faron 2023 Half-Year Financial Results |
| 07:00 | 04-08-2023 | FARN | Faron Pharmaceuticals Oy | Notice of Half-Year Financial Results |
| 07:00 | 25-07-2023 | FARN | Faron Pharmaceuticals Oy | Grant of Options |
| 07:00 | 19-07-2023 | FARN | Faron Pharmaceuticals Oy | BEXMAB study update |
| 16:52 | 30-06-2023 | FARN | Faron Pharmaceuticals Oy | Holding(s) in Company |
| 07:00 | 29-06-2023 | FARN | Faron Pharmaceuticals Oy | Announcement of Placing |
| 07:00 | 12-06-2023 | FARN | Faron Pharmaceuticals Oy | Exercise of options |
| 07:00 | 05-06-2023 | FARN | Faron Pharmaceuticals Oy | Board Member to Assume Transactional Advisor Role |